Literature DB >> 27864582

[Skin diseases due to systemic vasculitides and vasculopathies].

S Volc1, J C Maier1, M Röcken2.   

Abstract

Vasculitis and vasculopathy are two distinct disease entities. Each entity comprises a large number of heterogeneous diseases, which can occur alone or associated with autoimmune, infectious or neoplastic diseases. The terms vasculitis and vasculopathy are often falsely used synonymously. A vasculitis initially causes inflammation of the vessel walls that may result in a secondary occlusion. In contrast, a vasculopathy is a primary occlusion of the vascular lumen, which is followed by inflammation after ischemia and ulceration. In most patients the distinction can be made based on the clinical presentation. A clear clinical diagnosis is then followed by targeted serological, histological and imaging procedures to confirm the clinical diagnosis. On this basis a well-founded treatment can be initiated. In the presence of vasculitis an anti-inflammatory therapy is indicated, whereas in the case of vasculopathy, removal of the vascular occlusion is the main focus. This article provides an overview of the various diseases and addresses the pathogenetic and clinical characteristics used to differentiate the individual disease entities. It also provides an insight into the therapy options and prophylaxis.

Entities:  

Keywords:  Inflammation; Ischemia; Prophylaxis; Therapy; Vascular occlusion

Mesh:

Substances:

Year:  2016        PMID: 27864582     DOI: 10.1007/s00105-016-3896-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  36 in total

1.  Livedo reticularis with summer ulcerations.

Authors:  M FELDAKER; E A HINES; R R KIERLAND
Journal:  AMA Arch Derm       Date:  1955-07

2.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

3.  Direct immunofluorescence of skin biopsy: perspective of an immunopathologist.

Authors:  Ranjana Walker Minz; Seema Chhabra; S Singh; B D Radotra; Bhushan Kumar
Journal:  Indian J Dermatol Venereol Leprol       Date:  2010 Mar-Apr       Impact factor: 2.545

Review 4.  Vasculitides in hairy cell leukemia.

Authors:  P Hasler; H Kistler; H Gerber
Journal:  Semin Arthritis Rheum       Date:  1995-10       Impact factor: 5.532

5.  Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.

Authors:  J W Bard; R K Winkelmann
Journal:  Arch Dermatol       Date:  1967-11

6.  Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study.

Authors:  Wen-Liang Chang; Yao-Hsu Yang; Li-Chieh Wang; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Pediatr Nephrol       Date:  2005-06-10       Impact factor: 3.714

7.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 8.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

Review 10.  Developments in Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.